The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Daratumumab, a CD38 mab, for the treatment of relapsed/refractory multiple myeloma patients: Preliminary efficacy data from a multicenter phase I/II study.
Torben Plesner
Consultant or Advisory Role - Genmab
Honoraria - Genmab
Expert Testimony - Genmab
Henk M Lokhorst
Consultant or Advisory Role - Genmab
Research Funding - Genmab
Peter Gimsing
No relevant relationships to disclose
Hareth Nahi
No relevant relationships to disclose
Steen Lisby
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Paul Gerard Guy Richardson
Consultant or Advisory Role - Genmab